Key Highlights:
- Aardvark Therapeutics shares fell 43.04% to $2.25 on Friday, October 23, 2026.
- The FDA lifted the full clinical hold on ARD-101 on October 22, 2026, after the hold was announced in May.
- The terminated HERO trial randomized 67 of 90 planned participants, and efficacy data were exploratory.
- Cash and investments were $73.9 million on June 30, 2026, down from $91.2 million on March 31.
- The company expects to resume Prader-Willi syndrome clinical activities in 2027.
Aardvark Therapeutics Stock: Why Did Shares Fall 43% After the FDA Lifted the Hold?
Aardvark Therapeutics (NASDAQ:AARD) shares fell 43.04% to $2.25 on Friday, October 23, 2026, from a prior close of about $3.95 (calculated). The decline came on the day the company published exploratory data from its terminated Phase 3 HERO trial and the open-label extension study of ARD-101, a treatment for hyperphagia in Prader-Willi syndrome.
The data followed an October 22 announcement that the FDA had lifted the full clinical hold on ARD-101. The hold was disclosed in May 2026, and the company terminated the HERO and extension trials in June.
The new data showed a modest reduction in hyperphagia scores against placebo at week two of dose escalation. After treatment was stopped, scores in the ARD-101 group returned to near baseline, while the placebo group rebounded less.
HERO and Extension Trial Results: What Did the Exploratory Data Show?
HERO randomized 67 of 90 planned participants, or about 74% (calculated). All efficacy findings are exploratory because the trial ended early.
Caregiver and clinician measures showed a similar pattern. In the open-label extension, participants who switched from placebo to ARD-101 had an average reduction of 6 points on the HQ-CT hyperphagia scale.
The company said ARD-101 was generally well tolerated and that most adverse events were mild to moderate. One serious cardiac event occurred in HERO at a dose of 800 mg twice daily in a participant also taking pitolisant, and the FDA agreed it was related to a drug interaction.
Next Steps for ARD-101: What Is the Plan After the Hold Is Lifted?
Dosing will resume at a level below 800 mg twice daily, pending discussion with the FDA. Aardvark plans to request an FDA meeting to align on a new Phase 3 design.
The company expects to resume clinical activities in Prader-Willi syndrome in 2027. No design or topline date for the new study has been announced.
ARD-101 is Aardvark's main program in Prader-Willi syndrome.
Cash and Financial Context: How Much Runway Does Aardvark Have?
In its second-quarter report on August 11, 2026, the company reported cash, cash equivalents and short-term investments of $73.9 million at June 30. That compared with $91.2 million at March 31, a decline of $17.3 million in the quarter (calculated).
Net loss was $14.4 million for the quarter, flat from a year earlier, and $36.0 million for the first six months of 2026. Research and development expense fell to $10.5 million from $13.1 million.
Management said cash should fund projected operations into late 2027.
What to Watch Next: Can Aardvark Win Agreement on a New Phase 3 Design?
The takeaway is that the FDA hold lift removed a regulatory barrier, while the exploratory data led investors to reassess the size of the treatment effect. The next dated checkpoint is the third-quarter financial report, for which the company has not announced a date, with the prior second-quarter report issued on August 11. A meeting with the FDA on the new trial design is the key clinical milestone to follow.
The company reported exploratory data from the terminated HERO and extension trials showing a modest effect, and shares fell 43.04% to $2.25.
Yes, the company announced on October 22, 2026 that the FDA lifted the full clinical hold.
Cash, cash equivalents and short-term investments were $73.9 million on June 30, 2026, with runway projected into late 2027.






Please wait processing your request...